Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not only does this have nothing to do with us but you can't even do simple math. 20B + 5B + 5B = 30B, not 35B. LOL!
If so, here's the breakdown for that.
Bank of America, Citigroup, JPMorgan Chase and Wells Fargo announced today they are each making a $5 billion uninsured deposit into First Republic Bank.
Goldman Sachs and Morgan Stanley are each making an uninsured deposit of $2.5 billion.
BNY-Mellon, PNC Bank, State Street, Truist and U.S. Bank are each making an uninsured deposit of $1 billion, for a total deposit from the eleven banks of $30 billion.
https://www.zerohedge.com/markets/first-republic-bank-shares-crash-exploring-strategic-options
Link?
Only the Underwriters can give you a precise answer to your question. Anyone else's answer is simply going to be a guess. So, how it looked +10 years ago the Underwriters had a $28 million Class 18 claim and a $72 million Class 20 claim. With the eventual approval of POR7, the Underwriters negotiated to drop the Class 18 claim while retaining their $72 million Class 20 claim, (their Class 20 claim then became a Class 19 claim). With their Class 19 claim they received WMIH Common Shares, something they wouldn't have received having their Class 18 claim.
Keep in mind that the belief +10 years ago was that the waterfall wasn't going to reach any further than Class 16 (Piers), with Class 16 being left impaired. (not even being paid in full.) So, even if the Underwriters had negotiated to retain their $28 million Class 18 and give up their Class 20 claim there still was no guarantee that their Class 18 claim was to be paid in full, much less to see any payment at all. That's how it looked +10 years ago.
From a discussion on Reddit...
From Revive's patent from March 16th, 2021: "Preliminary indications are that none of the patients receiving Bucillamine in the trial have to date been hospitalised for COVID-19 or have died from COVID-19."
https://www.reddit.com/r/RVVTF/comments/r9ug7u/from_revives_patent_from_march_16th_2021/
However, there's no mention about the 1 placebo death or placebo hospital admissions.
All this cash that you've supposedly have made still hasn't helped you to change your character to being a better person.
Elvis is still alive as well. And, he's running WaMu.
You've been on Boardpost just as long as i have. Therefore, you should also be a witness to all of his nonsense when he was still there. The so-called documented proof of a $24 billion FDIC "Settlement" in which was presented by him in late 2016/early 2017 as genuine was false. We're now a month later since AZCowboy has stated that he's supposedly received a payment for his WMB Notes, yet no other Note Holder has received theirs. Seriously - think!
I'll reiterate...
https://www.boardpost.net/forum/index.php?topic=15468.msg340084#msg340084
XXXX is a figment of AZCowboy's imagination. He's making XXXX up, which is why he doesn't just come out and simply state what XXXX is. It's a game he's playing. This is what he does. He'll make something up because he wants others to believe he is extremely knowledgeable and that he's the only one with such inside secrets. He wants others to hang on every word of his.
Personally, i find it rather entertaining because i became aware of his game many, many, many, years ago. I absolutely do not find it entertaining for others who don't know any better to what he's really trying to do; and he should be ashamed of misleading others with purposeful misinformation and falsehoods being presented as genuine.
WMI Investment Corp. (“WMIIC”) wasn't “eliminated upon consolidation”, it was dissolved. (+5 years ago) It no longer exist.
"On January 18, 2018, WMIH Corp. (the “Company”) announced that it has completed the dissolution of its wholly-owned subsidiary WMI Investment Corp. (“WMIIC”). Earlier today, WMIIC filed a Certificate of Dissolution of WMIIC with the Office of the Delaware Secretary of State. The dissolution of WMIIC was effective immediately upon the filing of such certificate.
Prior to September 26, 2008, WMIIC held a variety of securities and investments; however, such securities and investments were liquidated and the value thereof distributed in connection with implementing the Company’s Seventh Amended Joint Plan of Affiliated Debtors Pursuant to Chapter 11 of the United States Bankruptcy Code. As such, WMIIC did not have any assets or operations at the time of its dissolution."
https://www.sec.gov/Archives/edgar/data/933136/000156459018000606/wmih-8k_20180118.htm
I'm aware that there's more but it doesn't add to the point i was making; the point being that WMI Washington does not exist as a separate entity, unlike what AZCowboy chooses to believe.
WMI Washington no longer exists.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171399662
Why do you continue to present the false narrative that it does exist?
WMI Washington no longer exists, no matter how many times you say it or wish for it to.
"As disclosed below, WMIH Corp., a Delaware corporation (f/k/a WMI Holdings Corp.) (“WMI Delaware” or the “Company”) became the successor to WMI Holdings Corp., a Washington corporation (“WMI Washington”), on May 11, 2015."
"As further described in Item 3.03 below, WMI Washington consummated a reincorporation merger (the “Reincorporation”) with and into its wholly owned subsidiary, WMI Delaware, pursuant to the terms of an Agreement and Plan of Merger entered into between WMI Washington and WMI Delaware on May 11, 2015 (the “Merger Agreement”), which is attached as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference. The effective time and date of the Reincorporation was 8:00 p.m. Eastern time on May 11, 2015 (the “Effective Time”). As a result of the Reincorporation, the registrant is now a Delaware corporation and WMI Washington has ceased to exist."
https://www.sec.gov/Archives/edgar/data/933136/000119312515186101/d924385d8k12g3.htm
This is case filing from 1/30/20 in which Nationstar Mortgage, LLC is listed as the Defendant. It's a Corporate Disclosure statement.
https://www.docketbird.com/court-documents/Jech-v-Nationstar-Mortgage-LLC/Corporate-Disclosure-Statement-identifying-Other-Affiliate-Nationstar-Mortgage-LLC-for-Nationstar-Mortgage-LLC-filed-by-Nationstar-Mortgage-LLC/ohnd-1:2019-cv-02271-00016
Here's the breakdown.
Mr Cooper Group Inc (COOP; formally know as WMIH Corp. (WMIH)) is a Delaware corporation. - the parent
Nationstar Mortgage Holdings Inc. (NSM; which WMIH Corp acquired in 2018) is a wholly-owned subsidiary of Mr. Cooper Group Inc.
Nationstar Sub1 LLC and Nationstar Sub2 LLC are are both 100% owned by Nationstar Mortgage Holdings Inc. (NSM)
Nationstar Mortgage LLC is a Delaware Limited Liability Company. It is directly owned by Nationstar Sub1 LLC and Nationstar Sub2 LLC and it is an indirect, wholly-owned subsidiary of Mr Cooper Group Inc (COOP).
There is no (XXXX). (XXXX) is simply a fabrication by you.
How peculiar it is that you seem to be the only WMB Note Holder who's received any such payment for your WMB Notes. Do you really believe you're more special than any other WMB Note Holder? It's either very strange or your information on the matter is highly suspect. I think the latter. And, i still say any payment you might have received from Wells Fargo was in regards to this.
https://www.cnbc.com/2023/01/19/wells-fargo-might-owe-you-money-how-to-get-it.html
(But, this highly likely reason simply wouldn't be impressive to anyone nor would anyone feel envious of you.)
((Also, your information about there being an FDIC $24 billion payment, (with a drop dead date of March 2017; the "Settlement", which you claimed there was documented proof) was also highly suspect in 2017. Do you have any updates for us on this "Settlement", now? ))
The problem with you (and AZCowboy) is you're stuck in the past trying to decipher some magical codes and refuse to acknowledge the changing events that have happened since.
This isn't the year 2015, it's the year 2023. WMIH shares no longer trade (or exist). In 2018 WMIH Corp (WMIH) became Mr Cooper Group Inc (COOP). WMIH shares were exchanged for COOP shares, with WMIH shares being cancelled.
Now, the Registrant is Mr Cooper Group Inc. Unlike some who want to believe that COOP is a subsidiary of a subsidiary of "(XXXX)", it's not. Mr Cooper Group Inc is the Parent.
Stop being cryptic and just state "who' (XXXX) is", since you seem to imply that you know. However, it's more likely that you just want others to believe you have such knowledge but you're really just like a kid saying, "I know something that you don't know", with the reality that you're just creating a falsehood.
Not correct.
WMI WA = WMI Holdings Corp (WMIHC) and WMI Delaware = WMIH Corp. (WMIH).
"As disclosed below, WMIH Corp., a Delaware corporation (f/k/a WMI Holdings Corp.) (“WMI Delaware” or the “Company”) became the successor to WMI Holdings Corp., a Washington corporation (“WMI Washington”), on May 11, 2015."
"As further described in Item 3.03 below, WMI Washington consummated a reincorporation merger (the “Reincorporation”) with and into its wholly owned subsidiary, WMI Delaware, pursuant to the terms of an Agreement and Plan of Merger entered into between WMI Washington and WMI Delaware on May 11, 2015 (the “Merger Agreement”), which is attached as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference. The effective time and date of the Reincorporation was 8:00 p.m. Eastern time on May 11, 2015 (the “Effective Time”). As a result of the Reincorporation, the registrant is now a Delaware corporation and WMI Washington has ceased to exist. "
https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-15-186101.html?hash=08530bed64fd3c4614bd32d50d0e45ad3ce4a8401fcdacce8eb9bed2199b69b4&dest=D924385DEX105_HTM#D924385DEX105_HTM
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
https://www.globenewswire.com/news-release/2022/10/06/2529697/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html
TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
Further to the Company’s recent submission of the Study’s amended protocol, the Company has been in communication with the FDA to submit a revised protocol with a new primary efficacy endpoint, specifically, assessing the difference in the proportion of participants with at least two clinical improvements in symptoms of COVID-19 at Day 14 compared with baseline between Bucillamine versus placebo. Additional secondary endpoints may include clinical outcome (death or hospitalization), the time to the polymerase chain reaction resolution, disease severity, supplemental oxygen use, and progression of COVID-19. The Company expects to submit the revised protocol next week. Should the FDA agree with the revised protocol, the Data Safety Monitoring Board (“DSMB”) will review the completed Post-Dose selection data of approximately 500 subjects in the context of the new primary endpoint. The DSMB may recommend continuing the Study if there is a trend toward achieving statistical significance, halting the Study early due to statistical significance likely not going to be met, or halting the Study early due to positive efficacy showing statistical significance. Regardless of the outcome, the Company would proceed to seek a meeting with the FDA to agree on a proposed plan for potential regulatory approval.
The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Revive Therapeutics To Schedule DSMB Meeting In Lieu Of FDA Decision
https://thedalesreport.com/psychedelics/revive-therapeutics-to-forge-ahead-with-dsmb-meeting-despite-fda-decision/
Revive Therapeutics Ltd. (CNSX: RVV) (OTCMKTS: RVVTF) obtained a material ruling from the U.S. Food & Drug Administration (FDA) pertaining to its current Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19. While dour sentiment was reflected on the public exchanges, the ruling does not explicitly change the trajectory of the trial, from an analytical perspective.
On Wednesday, Revive Therapeutics announced that pursuant to its intention to pursue new primary symptoms endpoints, the FDA determined that Revive’s proposed amended endpoint protocol, while still under review, does not support the time to resolution via the polymerase chain reaction (PCR) test. The PCR data was envisioned to be an important supportive biomarker in measuring time to resolution of symptoms and secondary endpoints in patients with mild-moderate COVID-19 receiving Bucillamine therapy compared with those receiving placebo.
However, the FDA’s determination does not mean that Revive’s trial is over, or even necessarily diminished—at least from a analytical perspective. The company still intends to pursue a Data Safety Monitoring Board (DSMB) meeting to review statistical trial data and advance the study:
"As a result, to potentially obtain FDA agreement and strengthen the relevance of the revised endpoint, which relied upon the Study’s Pre-Dose selection data, the Data Safety Monitoring Board (“DSMB”) will review the completed Post-Dose selection data of approximately 500 subjects… Regardless of the outcome, the Company would proceed to seek a meeting with the FDA to agree on a proposed plan for potential regulatory approval..."
Pursuant to a prospective DSMB meeting, the committee shall offer one of several possible courses of action:
• Make a recommendation on continuing the study by enrolling additional patients
• Advise on halting the study early due to positive efficacy showing statistical significance
• Recommend halting the trial due to lack of safety and/or efficacy
So while Wednesday’s FDA ruling undoubtedly takes Revive Therapeutics’ COVID-19 trial down a more winding path, the DSMB will remain the ultimate arbiter of trial outcome. This includes possibility of providing valuable feedback (i.e. trend analysis pertaining to the resolution of symptoms) to Revive as it inevitably attempts to re-engage endpoint swap discussions with the FDA.
Revive Remains In Discussion With The FDA
Although today’s news was not a best-case scenario for Revive, it was far from an outright rejection that could have diminished the trial’s prospects significantly. The FDA simply set preliminary parameters on which types of endpoints, and the basis thereof, that it is willing to consider before moving forward, but is keeping the discussion going. The press release explicitly states that the FDA is amenable to meeting further “to discuss the appropriate endpoints and justification of the relevance of the revised primary endpoint.”
Therefore, the FDA has not slammed the door on potential endpoint change submission. Is it simply seeking the appropriate justification and relevant data points in which to do so.
According to Revive CEO Michael Frank, whom TDR spoke with earlier today, DSMB input in the next phase will be important in determining next steps towards endpoint protocol resolution. “We look forward to presenting additional post-dose selection data covering approximately 500 trial patients to the DSMB,” said Mr. Frank. “From there, we anticipate receiving valuable feedback that may be used to further negotiations with the FDA regarding revised endpoint submission. This is our next point of focus in the coming weeks.”
Final Thoughts
While today’s decision may be interpreted as a setback for Revive, it’s essential to note that the FDA’s ruling was conceptual, not statistical. The FDA does not believe that PCR data should be the primary basis of new symptoms endpoints sought by Revive, so another path must be chosen. However, in no way does the FDA’s ruling reflect on the robustness, or lack thereof, of Revive’s patient data. It is predominantly a procedural obstacle in which the FDA is amenable to revisit once new protocols are developed.
TDR will have additional coverage as warranted.
31:12
The timing of submission? I mean I can’t answer that, we’d have to see. Obviously, we submitted a protocol. I mean, this is a very very important document. It’s you know, uh, it took a bit of time so things just don’t happen in a day. Yeah, we may have missed time lines on that, you know, it took four weeks instead of two, but it had to be done right.
And, uh, it’s hard for me to put a time on DSMB. But obviously, if we have the data that supports the approval, you know obviously, that’s the most important thing.
6 more days till Annual and Special Meeting Of Shareholders.
Biden Admin Wasting $10.6 Billion On Pfizer's COVID-19 Paxlovid Flop
https://www.zerohedge.com/covid-19/biden-admin-wasting-106-billion-pfizers-covid-19-paxlovid-flop
Pfizer Altered its Paxlovid Protocol. . . After Receiving its first $5.3 billion:
As we can see, FDA Emergency Use Authorizations (EUAs) don’t always work out as they should, but in this case, it was because of some manipulative action by Pfizer and an outrageous and risky bet by the Biden White House.
That’s because with no public mention, Pfizer had secretly lowered its own bar following its EUA after the White House had committed to purchasing $5.3 billion dollars of product. Pfizer stated:
“Following the Emergency Use Authorization of Paxlovid for individuals at high risk of progression to severe COVID-19, the protocol was amended to exclude high-risk individuals and allow enrollment of patients without risk factors for progression to severe COVID-19 who were either unvaccinated, or whose last COVID-19 vaccination occurred more than 12 months from enrollment.” (emphasis added)
This way, Pfizer was able to administer its drug to a less severely ill, and healthier population in hopes of having a superior efficacy signal and a decreased safety signal, but it still failed to show an adequate clinical effect on any of its prospective protocol-established endpoints.
According to Revive's most recent Quarterly Financial Statements filing on May 30, they have an unlimited number of common shares authorized.
Why would a reverse split be necessary to procure funding? In February 2021, Revive raised $23,000,000 in an Offering. ("46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000")
("Each Unit is comprised of one common share of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.70 per Common Share until February 12, 2024. If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “Exchange”) is greater than $1.10 for the preceding ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date on which the Company issues a press release announcing the reduced warrant term.")
If we see favorable results with Bucillamine then Revive's share price will reflect the favorable results. Revive could then procure additional funding through the warrants or do a similar Offering at a higher share price. Dilutive, yes...but a reverse split is not necessary.
From the Tweet - "OTCQB or better is in our sites $snpw"
Yet, they don't know the grammatical difference between sites and sight(s).
Revive Therapeutics corporate presentation for January 2022.
https://revivethera.com/wp-content/uploads/2022/01/RVV-Deck-January-2022.pdf
That's not how the PR reads.
"To date, the Study has screened approximately 700 subjects."
"In light of Phase 3 clinical studies and FDA approvals of oral antiviral treatments by Pfizer and Merck, it was evident that to ensure a diversified patient population to support future global regulatory submissions for Bucillamine, including the FDA, the Company has decided to fill a part of its patient enrollment quota outside of the U.S. and target Eastern Europe, such as in Turkey"
Pfizer's COVID Pill Stops Hospitalizations, But Not Milder Symptoms
https://www.zerohedge.com/covid-19/pfizers-covid-bill-stops-hospitalizations-not-milder-symptoms
In addition to making dramatic inroads for patients who are at high risk, the preliminary analysis showed the drug may also help people at low risk of severe COVID - for example, vaccinated patients who fall victim to a breakthrough infection - avoid becoming seriously ill. The data showed the drug reduced risk of hospitalization by 70%, although it failed to reduce or resolve symptoms within three or four days, suggesting it will be of limited use for patients only suffering from mild symptoms.
Great Video.
Maybe i'm wrong but my understanding is that the GenViro! Covid-19 Saliva Swift Kit is Keith Berman himself.
You would need to set up an appointment time with KB to be tested.
The Saliva Swift Kit testing process involves you spitting on KB. He would then proceed to pull a coin out of his pocket and flip it to determine your results, all within less than 15 seconds.
Yet, there is no mention of Decision Diagnostics or it's GenViro! Covid-19 Saliva Swift Kit.
The last official Press Release for DECN was in December, 2020. We're now in the latter part of October 2021.
Think on that.
Oh, here is the last PR. Classic Keith Berman.
DECN to Announce Various Testing Results This Week for Its COVID-19 GenViro! Swift Kit
https://www.accesswire.com/621860/DECN-to-Announce-Various-Testing-Results-This-Week-for-Its-COVID-19-GenViro-Swift-Kit
"Proceed With Caution At Your Own Peril" - Merck's COVID 'Super Drug' Poses Serious Health Risks, Scientists Warn
"As it turns out, all the scientists and doctors who insisted that Merck's "revolutionary" COVID drug molnupiravir is extremely safe weren't faithfully adhering to "the science" after all. Because according to a report published Thursday by Barron's, some scientists are worried that the drug - which purportedly cut hospitalizations in half during a study that was cut short - could cause cancer or birth defects.
So much for having a "strong safety profile," as Dr. Scott Gottlieb claimed in an interview on the day Merck first publicized the research."
(More to read at link...)
https://www.zerohedge.com/covid-19/proceed-caution-your-own-peril-mercks-covid-super-drug-poses-serious-health-risks
Perhaps you could send an email to the Company, specifically to Michael Frank, about any concerns you might have.
Also, the Pfizer study on PF-07321332/Ritonavir shows on the clinicaltrials.gov site (updated August 23) as not yet recruiting. It also shows an estimated primary completion date of October 18, 2021 and an estimated study completion date of February 28, 2022.
3 More sites added.
Avant Research Associates, LLC
Huntsville, Alabama, United States, 35802
SRI International
Plymouth, Michigan, United States, 48170
Great Lakes Research Institute
Southfield, Michigan, United States, 48075
Estimated Primary Completion Date : October 31, 2021
Estimated Study Completion Date : October 31, 2021
https://clinicaltrials.gov/ct2/show/NCT04504734
Revive Therapeutics (RVVTF) trades on the OTCQB, or did you not know that?
https://revivethera.com/2021/06/revive-therapeutics-approved-to-trade-on-the-otcqb-market/
Doubtful? The article talks about an American-made coronavirus drug.
Ministry of Health of Ukraine reserves 300 thousand doses of American medicine for COVID-19 in the form of pills
An American-made coronavirus drug in the form of tablets may appear in Ukraine, 300 thousand doses have already been reserved for Ukrainians. This was announced by the head of the Ministry of Health Viktor Lyashko in a comment to LB.ua.
According to the minister, the innovative drug is already undergoing the third stage of clinical trials - it is expected that it will have a specific effect on COVID-19.
Ukraine has reserved a batch of tablets, but has not paid yet.
The minister did not reveal the name of the drug, but it is known that in March 2021, Pfizer Inc began the first phase of clinical trials of oral antiviral therapy for COVID-19 in the form of tablets in the United States .
The Pfizer CEO said the experimental drug could go on sale by the end of 2021 .
Reuters noted that the Pfizer candidate is the third COVID-19 drug currently being tested. The first was developed by the American company Merck & Co., the second - by the Swiss Roche Holding together with the American Atea Pharmaceuticals.
https://translate.google.com/translate?hl=en&sl=ru&u=https://gordonua.com/news/society/minzdrav-ukrainy-zarezerviroval-300-tys-doz-amerikanskogo-lekarstva-ot-covid-19-v-vide-tabletok-1564153.html&prev=search&pto=aue